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Abstract 
Background and purpose: Individual markers of cerebral small vessel disease and cerebral 
atrophy explain a small proportion of variance in vascular risk factors and cognitive function. 
Combining these markers into a single measure of neurovascular and neurodegenerative 
disease may be more powerful. We assessed this using data contained in the Virtual 
International Stroke Trials Archive (VISTA) Prevention sub-archive.  
 
Methods: We extracted white matter hyperintensities (WMH) and cerebrospinal fluid (CSF) 
volumes from 317 people with ischaemic stroke or transient ischaemic attack who had a 
baseline MRI, and assessed progression of volumes in 208 people who had two-year follow-
up MRI. WMH and CSF volumes were segmented from FLAIR and T1 images. The 
combined neurovascular and neurodegenerative measure was the sum of WMH and CSF 
volume normalised by intracranial volume. We assessed: 1) the relationship between baseline 
vascular risk factors and imaging markers; and 2) the relationship between baseline imaging 
markers and mini mental state examination (MMSE) score at follow-up using multiple linear 
regression. We also assessed implications for sample size calculations using N=208 
participants with follow-up MRI. 
 
Results: Vascular risk factors accounted for 7%, 11%, and 12% of the variance in WMH, 
CSF, and combined volume, respectively (all P<.001). The association between baseline 
combined volume and six-month follow-up MMSE (ꞵ=-0.442, standard error (SE)=0.07, 
P<.0001) was 32% greater than WMH (ꞵ=-0.302, SE=0.06, P<.0001) and 12% greater than 
CSF (ꞵ=-0.391, SE=0.07, P<.0001) alone. The combined volume required between 207 and 
3305 (20%) fewer patients per arm than WMH alone to detect reductions of 10-40% in 
volume progression over two years. 
 
Conclusions: A combined neurovascular and neurodegenerative MRI measure including 
WMH and CSF volume was more closely related to vascular risk factors and cognitive 
function than either WMH or CSF volume alone. The combined volume may be a more 
sensitive measurement for clinical trials.   
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Introduction 
Combined measures of neurovascular and neurodegenerative features on magnetic resonance 
imaging (MRI) have recently been proposed to better characterise age- and stroke-related 
brain tissue damage1,2. The “Total Small Vessel Disease (SVD) Score” was based on 
combinations of clinical visual scores1 and the “Brain Health Index (BHI)” was based on 
automated processing of several MRI sequences2. The Total SVD Score has limited 
granularity and is prone to ceiling effects while the BHI requires high resolution T1, T2, 
FLAIR, and GRE sequences to be robust. These sequences may not always be available, 
particularly in studies using routine clinical imaging and/or in those designed to assess white 
matter hyperintensities (WMH) and other features of SVD using visual ratings, where thicker 
MRI slices may have been obtained. 
WMH volumes and measures of atrophy, e.g., cerebrospinal fluid (CSF) volume, may still be 
acquired from thicker slice images and only require FLAIR and T1 MRI. Individually these 
volumes are related to vascular risk factor burden, however vascular risk factors have been 
shown to explain very little of their variance3,4. Further, these volumes are related to 
cognitive impairment but the relationship is often weak2,5. It is unknown whether these 
individual volumes can be combined to better predict cognitive impairment. 
This study assessed whether a combined measure of WMH and CSF volume could: 1) 
increase variance accounted for by vascular risk factors in stroke-related brain MRI features; 
2) improve predictions of cognitive impairment; and 3) reduce sample sizes required to detect 
potential treatment effects in clinical trials. 
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Methods 
Participant and data extraction 
Data were obtained from the Virtual International Stroke Trials Archive (VISTA) Prevention 
sub-archive (http://virtualtrialsarchives.org/vista). VISTA holds fully anonymised data from 
completed clinical trials, negating the need for local ethical approval. The project was approved 
by the VISTA steering committee. We extracted baseline and two-year follow-up MRI, Mini-
Mental State Examination (MMSE) scores at six months (to limit confounding effects of stroke 
on cognition at baseline) and two-year follow-up, and vascular risk factors at baseline, where 
available. Vascular risk factors included reported diagnosis of hypertension, 
hypercholesterolemia, diabetes, smoking, atrial fibrillation and measured systolic and diastolic 
blood pressure. All data that we generated in this study will be made publicly available in 
VISTA and requests for access can be made at http://virtualtrialsarchives.org/vista. 
 
Brain MRI acquisition and processing 
Brain MRI was acquired at baseline and two-year follow-up; acquisition parameters are fully 
described in supplementary material Table I (please see http://stroke.ahajournals.org). The 
methods for WMH, CSF, and intracranial (ICV) volume processing using T1 and FLAIR 
images have been described previously7. All volumes were visually verified and WMH were 
checked and edited according to STRIVE guidelines8. WMH and CSF volumes were 
normalised (divided) by ICV. The combined neurovascular and neurodegenerative MRI 
measure was simply the sum of normalised WMH and normalised CSF volume. 
 
Statistical analysis 
All statistical analyses were performed using the Statistical Analysis System (SAS) version 
9.4 (© 2002-2012 SAS Institute Inc.). PROC REG was used to perform linear regression 
analyses between brain volumes, vascular risk factors, and MMSE using N=317 baseline 
participants. All regression beta (ꞵ) coefficients were standardised and compared with percent 
differences calculated as: ((ꞵ1-ꞵ2)/ꞵ1)*100. PROC POWER was used for sample size 
calculations with brain volume progression data from N=208 participants. Sample size 
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calculations were based on detecting reductions of 10-40% in the change from baseline to 
two-year follow-up in each brain volume with power=0.8 and alpha=0.05. 
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Results 
 
Participant Characteristics 
Characteristics of all 317 participants at baseline, divided by those that had a useable follow-
up MRI and those that did not, are in supplementary material Table II (please see 
http://stroke.ahajournals.org); N=208 participants had a useable follow-up MRI. Reasons for 
lack of a useable follow-up MRI included image artefact/motion and participant loss to 
follow-up. There were limited differences between participants that had a useable follow-up 
MRI and those that did not: death during study (a main reason for loss to follow-up) was 
higher in those without a follow-up MRI, and incidence of diabetes and diastolic blood 
pressure were higher in those with a follow-up MRI, as shown in supplementary material 
Table II (please see http://stroke.ahajournals.org). 
 
Variance in individual and combined brain MRI volumes accounted for by vascular risk 
factors 
Vascular risk factors accounted for 7% of the variance in WMH volume (F=4.03, P=0.0003), 
11% of the variance in CSF volume (F=5.64, P<.0001), and 12% of the variance in combined 
WMH and CSF volume (F=6.28, P<.0001) in N=317 participants. Full regression tables for 
vascular risk factors are in supplementary material, Tables III-V (please see 
http://stroke.ahajournals.org).   
 
Associations between individual and combined brain MRI volumes at baseline and cognition 
at six months 
Standard beta for the association between combined WMH and CSF volume and MMSE at 
six months (ꞵ=-0.442, standard error (SE)=0.07, P<.0001) was 32% greater than WMH alone 
(ꞵ=-0.302, SE=0.06, P<.0001) and 12% greater than CSF alone (ꞵ=-0.391, SE=0.07, 
P<.0001), when adjusting for vascular risk factors, age, and sex in N=317 participants. Full 
regression tables for MMSE are in supplementary material, Tables VI-VIII (please see 
http://stroke.ahajournals.org).   
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Prediction of two-year follow-up cognition via baseline brain MRI volumes 
The association between two-year follow-up MMSE, adjusted by MMSE at six months, and 
combined WMH and CSF volume (ꞵ=-0.219, P<.0001) was 31% greater than WMH (ꞵ=-
0.151, P=0.0005) and 11% greater than CSF (ꞵ=-0.194, P<.0001) alone. 
 
Changes in individual and combined brain MRI volumes and sample size calculations 
Changes in individual and combined brain MRI volumes in N=208 participants over two-year 
follow-up are in Table 1. Sample size calculations based on these changes and hypothesised 
reductions (treatments effects) of between 10 and 40 percent are in Table 2. Combined WMH 
and CSF volume had the greatest two-year change effect size (Cohen’s d=0.35) and required 
between 207 and 3305 participants (20%) less per arm than WMH volume alone, depending 
on hypothesised treatment effect (Table 2). 
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Discussion 
We have shown that vascular risk factors explain over one-third more of the variance in a 
combined WMH and CSF volume measure than WMH alone. Further, this combined 
measure better predicted post-stroke cognition than individual volumes. Furthermore, smaller 
sample sizes would be required to detect treatment effects in the combined measure 
compared to WMH and CSF alone. These results add to growing support for the use of 
combined brain damage metrics in stroke1,2. 
WMH are often referred to as “of presumed vascular origin” however, as with others3,4, we 
found that multiple vascular risk factors explained a very small proportion of variance in 
WMH. Although atrophy is often implicated in neurodegenerative rather than neurovascular 
conditions9, vascular risk factors explained approximately one-third more of the variance in 
CSF compared with WMH. Variance accounted for by vascular risk factors in the combined 
volume and CSF were very similar. 
WMH volume had the weakest association with MMSE (compared with CSF volume and the 
combined WMH and CSF volume) and this is consistent with previous work finding that 
WMH are more closely associated with individual cognitive domains rather than global 
cognitive function10. We will assess associations between individual and combined (WMH 
and CSF volumes) and individual cognitive domains in the XILO-FIST trial7. 
WMH volume has previously been shown to reduce required sample sizes for clinical trials 
over cognitive scores11. Our estimates for sample sizes required in a WMH trial are consistent 
with recent results from the Mild Stroke Study in Edinburgh that based sample size 
calculations on a hypothetical treatment stabilising and preventing progression of WMH6. 
The combined WMH and CSF measure developed here further reduced sample sizes required 
to detect hypothetical treatment effects by the low hundreds to several thousands, depending 
on effect size. However, even with a moderate treatment effect of 20%, the combined 
measure still required over three thousand participants per arm. Adding more tissue volumes 
and/or diffusion metrics to the combined brain damage measure may further reduce required 
sample sizes and this will be assessed in future. Additionally, individual measures may be 
given different weights in a future combined metric rather than simply computing their sum. 
Potential treatments for WMH and brain atrophy are currently being trialled7,12 and the 
totality of our results (greater variance accounted for by vascular risk factors, stronger 
associations with cognition, reduced sample size requirements), provides support for the use 
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of a combined WMH and atrophy measure in early phase studies designed to limit post-stroke 
brain degradation and tackle vascular cognitive impairment. 
Our work has limitations. As we used data from clinical trials there is the risk of confounding 
from relevant variables that were not assessed, and limited generalisability to patients not 
well enough or motivated to take part in a trial. We obtained a limited battery of vascular risk 
factors that did not include, for example, physical activity, diet and waist-hip ratio. However, 
we did acquire vascular risk factors that contribute to most of the population attributable risk 
of stroke13. One third of participants did not have a useable follow-up MRI and this limits the 
generalisability of our work to participants not well enough to return for a scan or lie still in 
the scanner at follow-up. However, these concerns are mediated by the limited differences 
between participants with and without useable follow-up MRI. WMH and CSF volumes 
required manual checking and editing, and this may limit application of our method to much 
larger samples. Several different scanners were used to acquire MRI however this replicates 
the reality of many clinical trials that are multisite. Further, inter-participant differences have 
long been shown to far outweigh inter-scanner differences and our results are similar to single 
scanner studies3,14. MMSE is a crude measure of global cognitive function and this may not 
be sensitive to vascular cognitive impairment which in turn may be more closely related to 
WMH. Additionally, we did not have assessments of cognition prior to stroke therefore could 
not adjust for premorbid cognitive ability. Finally, further work is required to understand 
WMH regression and brain volume reduction due to a decrease in interstitial fluid which may 
not have adverse clinical consequences. 
Notwithstanding these limitations, we have provided a new combined neurovascular and 
neurodegenerative MRI measure in stroke that strengthened associations with clinical and 
cognitive parameters and reduced sample size requirements for prospective clinical trials. 
These results provide support for the use of a combined WMH and atrophy measure in early 
phase studies designed to assess the efficacy of treatments for brain degradation and 
cognitive impairment in stroke. 
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Table 1. Mean changes in WMH, CSF, and combined volumes over two-year follow-up 
Volume* Baseline 
(Mean±SD) 
Two-years 
(Mean±SD) 
Mean difference 
(Mean±SD) 
Cohen’s d 
WMH 0.0091±0.0095 0.0102±0.0101 0.0012±0.0037 
(t=4.50, P<.0001) 
0.32 
CSF 0.2087±0.0367 0.2139±0.0333 0.0053±0.0181 
(t=4.19, P<.0001) 
0.29 
Combined 
(WMH+CSF) 
0.2177±0.0417 0.2241±0.0392 0.0064±0.0183 
(t=5.04, P<.0001) 
0.35 
Note: *volumes are normalised (divided by intracranial volume); SD=standard deviation; 
WMH=white matter hyperintensities, CSF=cerebrospinal fluid. 
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Table 2. N per group required to detect reductions in WMH, CSF, and combined volume 
progression over two-year follow-up 
Treatment 
effect* 
Volume  
40% 30% 20% 10% 
WMH 1011 1796 4040 16154 
CSF 1166 2073 4661 18641 
Combined 
(WMH+CSF) 
804 1429 3213 12849 
Note: *Treatment effects are hypothesised percent reductions in change from baseline to two-
year follow-up between active treatment and control in each volume. WMH=white matter 
hyperintensities, CSF=cerebrospinal fluid.  
 
 
